KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis.

Jiayu Wang, Qingyuan Zhang, Huiping Li, Zhongsheng Tong, Quchang Ouyang, Huihui Li, Yuee Teng, Biyun Wang, Tao Sun, Jingfen Wang, Wei Li, Zhaofeng Niu, Hongsheng Li, Chang Gong, Shu Wang, Xinshuai Wang, Xinhong Wu, Ning Liu, Guohua Yu, Fei Liu, Xianghui Duan, Shuya Wang, Yaping Meng, Li Wang, Binghe Xu

Nat Commun 16(1) 3350

PMID40204778
PMCIDPMC11982359
DOI10.1038/s41467-025-58647-z
发表日期2025-04-09
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

The BRIGHT-2 study (NCT05077449) is a randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy and safety of bireociclib plus fulvestrant (BF) vs. placebo plus fulvestrant (F) in Chinese female patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC) who had progressed on or after prior endocrine therapy (ET). Interim results were analyzed after 70% of progression-free survival (PFS) events across 64 centers in China between December 8, 2021, and March 28, 2023. Patients were randomized (2:1) to receive BF or F, with stratification based on visceral involvement (yes/no) and resistance to prior primary or secondary ET. As the primary outcome, PFS was significantly prolonged in the BF group (n = 204) (12.94 months; 95% CI: 11.07-not reached) compared to 7.29 months (95% CI: 5.45-11.04) in the F group (n = 101) (hazard ratio, 0.56; 95% CI: 0.39-0.80; p = 0.001). The objective response rate in the BF group was 39.7% in the intention-to-treat population. Grade ≥3 adverse events were more frequent in the BF group (64.7%) than in the F group (18.8%), with neutropenia, leukopenia, and anemia being the most common. These findings suggest that BF is a promising therapeutic option for patients with HR+/HER2- ABC following ET failure.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 2

Fig. 2. Kaplan–Meier plots of PFS per investigator (a) and BICR (b). BF bireociclib plus fulvestrant; BICR blinded independent central review; CI confidence interval; F placebo plus fulvestrant; HR hazard ratio; PFS progression-free survival.

A

Progression-free survival

Fig. 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal曲线 2:extreme upward reversal
查看结果
B

Progression-free survival

Fig. 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal曲线 2:extreme upward reversal
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1. CONSORT diagram. CONSORT Consolidated Standards of Reporting Trials.
非 KM Figure
Fig. 3Fig. 3. Progression-free survival of patients in subgroups per investigator. Data are presented as HRs for the BF group vs. the F group, with error bars representing 95% CIs, indicated by crossing horizontal lines. HRs are unstratified except the overall PFS, overall PFS estimates were stratified by visceral metastatic and ET resistance. BF bireociclib plus fulvestrant, CI confidence interval, ECOG Eastern Cooperative Oncology Group, ET endocrine therapy, F placebo plus fulvestrant, HR hazard ratio, mPFS median progression-free survival, No. numbers, PFS progression-free survival, PR progesterone receptor.
非 KM Figure